- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about REGN
Recent news which mentions REGN
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
March 01, 2023
From Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
February 22, 2023
Tickers
REGN
From Benzinga
2 Top Healthcare Stocks Defying the Bear Market
February 14, 2023
From Motley Fool
From InvestorPlace
Ocular Therapeutix Shares Jump On Favorable Data From Intravitreal Implant Study In Wet AMD
February 13, 2023
From Benzinga
2 Biotech Stocks That Could Help Set You Up for Life
February 11, 2023
From Motley Fool
From Benzinga
The 7 Best Biotech Stocks to Buy for February 2023
February 07, 2023
From InvestorPlace
Regeneron Pharmaceuticals Q4 Earnings: Revenue Falls As COVID-19-Related Sales Dwindle
February 03, 2023
Tickers
REGN
From Benzinga
Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact
February 03, 2023
From Benzinga
The 7 Most Undervalued Stocks to Buy in February 2023
February 02, 2023
From InvestorPlace
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
February 02, 2023
From InvestorPlace
The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023
February 01, 2023
From InvestorPlace
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
February 01, 2023
Tickers
REGN
From Benzinga
From Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
From InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
January 30, 2023
From Benzinga
Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis
January 30, 2023
From Benzinga
What 8 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
January 30, 2023
Tickers
REGN
From Benzinga
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
January 29, 2023
From Benzinga
Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023
January 23, 2023
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023
January 20, 2023
From Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
January 19, 2023
Tickers
REGN
From Benzinga
What This Drug News Could Mean for Sanofi Shareholders
January 08, 2023
From Motley Fool
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
January 06, 2023
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.